Transforming cancer treatment and advancing new therapies through empowered science.
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to...
NASDAQ | SGEN (Common Stock)
07/27/16 4:00 p.m. ET
Minimum 20 minute delay
Latest Investor Information
Press ReleasesSeattle Genetics Reports Second Quarter 2016 Financial Results 07/26/16Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood 07/18/16
Events2nd Quarter 2016 Financial Results07/26/16 4:30 p.m. ETView eventUBS Global Healthcare Conference05/24/16 10:30 a.m. ETView event
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|